In vitro detection of cholangiocarcinoma cells using a fluorescent protein-expressing oncolytic herpes virus
- PMID: 28409558
- DOI: 10.1038/cgt.2017.11
In vitro detection of cholangiocarcinoma cells using a fluorescent protein-expressing oncolytic herpes virus
Abstract
Pathological confirmation is desired prior to high-risk surgery for suspected perihilar cholangiocarcinoma (PHC), but preoperative tissue diagnosis is limited by poor sensitivity of available techniques. This study aimed to validate whether a tumor-specific enhanced green fluorescent protein (eGFP)-expressing oncolytic virus could be used for cholangiocarcinoma (CC) cell detection. Extrahepatic CC cell lines SK-ChA-1, EGI-1, TFK-1 and control cells (primary human liver cells) were exposed to the oncolytic herpes simplex type 1 virus NV1066 for up to 24 h in adherent culture. The technique was validated for cells in suspension and cultured cells that had been exposed to crude patient bile. Optimal incubation time of the CC cells with NV1066 at a multiplicity of infection of 0.1 was determined at 6-8 h, yielding 15% eGFP-expressing cells, as measured by flow cytometry. Cells were able to survive 2-h crude bile exposure and remained capable of producing eGFP following NV1066 infection. Detection of malignant cells was possible at the highest dilution tested (10 CC cells among 2 × 105 control cells), though hampered by non-target cell autofluorescence. The technique was not applicable to cells in suspension due to insufficient eGFP production. Accordingly, as yet the technique is not suitable for standardized clinical diagnostics in PHC.
Similar articles
-
Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer.Cancer Gene Ther. 2006 Jan 1;13(1):53-64. doi: 10.1038/sj.cgt.7700860. Cancer Gene Ther. 2006. PMID: 16037824 Free PMC article.
-
Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer.Hum Gene Ther. 2004 Jun;15(6):609-18. doi: 10.1089/104303404323142051. Hum Gene Ther. 2004. PMID: 15212719
-
Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.Cancer Lett. 2010 Feb 1;288(1):17-27. doi: 10.1016/j.canlet.2009.06.014. Epub 2009 Jul 14. Cancer Lett. 2010. PMID: 19604626
-
[Progess on research of herpes simplex virus type 1 mutants for cancer therapy].Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2008 Dec;25(6):1446-9. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2008. PMID: 19166228 Review. Chinese.
-
[The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].Bing Du Xue Bao. 2016 Jul;32(4):516-22. Bing Du Xue Bao. 2016. PMID: 29996042 Review. Chinese.
Cited by
-
A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma.Cancers (Basel). 2019 Oct 27;11(11):1667. doi: 10.3390/cancers11111667. Cancers (Basel). 2019. PMID: 31717883 Free PMC article.
-
Oncolytic Herpes Simplex Virus Prevents Premalignant Lesions from Progressing to Cancer.Mol Ther Oncolytics. 2019 Dec 6;16:1-6. doi: 10.1016/j.omto.2019.11.003. eCollection 2020 Mar 27. Mol Ther Oncolytics. 2019. PMID: 31909180 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources